Subscribe
p1images-istockphoto-com-money-
p1images / iStockphoto.com
29 November 2018Biotechnology

NHS to save £300m in biosimilar adalimumab deals

The National Health Service (NHS) England is set to make record-breaking savings after negotiating deals with five manufacturers of low-cost biosimilar versions of the NHS's most expensive drug.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
NHS partners with drugmakers to eliminate hep C
3 May 2019   The National Health Service, the UK’s government-run health system, has partnered with Gilead Sciences, Merck Sharp and Dohme and AbbVie to help eliminate hepatitis C in England.
Americas
AbbVie and Pfizer in Humira licensing deal
3 December 2018   AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Big Pharma
NHS partners with drugmakers to eliminate hep C
3 May 2019   The National Health Service, the UK’s government-run health system, has partnered with Gilead Sciences, Merck Sharp and Dohme and AbbVie to help eliminate hepatitis C in England.
Americas
AbbVie and Pfizer in Humira licensing deal
3 December 2018   AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.

More on this story

Big Pharma
NHS partners with drugmakers to eliminate hep C
3 May 2019   The National Health Service, the UK’s government-run health system, has partnered with Gilead Sciences, Merck Sharp and Dohme and AbbVie to help eliminate hepatitis C in England.
Americas
AbbVie and Pfizer in Humira licensing deal
3 December 2018   AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims